Bayer & #8217;s darolutamide plus androgen deprivation therapy (ADT) significantly extends metastasis-free survival with a favorable safety profile compared to placebo plus ADT in non-metastatic castration-resistant prostate cancer (for specialized target groups only)

Statistically significant improvement in metastasis-free survival (MFS), with a median MFS of 40.4 months with darolutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT (18.4 months) / Positive trend in overall survival with a 29% reduction in risk of death at interim analysis (P=0.045) / Incidence of treatment-emergent adverse events was similar for darolutamide plus ADT and placebo plus ADT / Health-related quality of life was maintained / First results from the Phase III ARAMIS trial with the androgen receptor antagonist darolutamide were presented in an oral presentation at American Society of Clinical Oncology Genitourinary Cancers Symposium and simultaneously published in The New England Journal of Medicine
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news